Cite
HARVARD Citation
Mariette, X. et al. (n.d.). THU0163 Early Response as A Predictor of Long-Term Clinical Response in DMARD-Naïve Patients with Severe, Active and Progressive RA Treated with Certolizumab Pegol plus Optimized MTX versus Optimized MTX Alone. Annals of the rheumatic diseases. p. 242. [Online].